Member Exclusive News

The week in industry: CAD$10 Million awarded to develop novel cancer therapies

This week: bluebird bio gains first approval for their gene therapy ZYNTEGLO™, the first and only drug for episodic cluster headaches approved by US FDA and more companies join the Quantum Leap project to improve novel intracellular delivery technology.

Thumb untitled design
Jun 06, 2019
0
0

Please sign in or register for FREE

No comments yet.